IP and Biotech: Is There a Road Map?

Experts share their experience and advice to advance an understanding of how IP affects the Biotechnology industry.

Event Details

Location

swissnex San Francisco
730 Montgomery St., San Francisco, 94111 United States

Date

May 11, 2006 from 7:30 am to 8:30 pm America/Los Angeles (UTC-08:00)

Intellectual Property (IP) is essential to the success of any life biotech company and a primary concern to investors, just as technology, marketing and management are.

The level of complexity of the issues, the costs, and the challenges faced among Offices of Technology Transfers (OTT) make IP a major headache for the whole industry. Adding to the complexity of the current regulations, the United States Patent Office (USPTO) is about to reform their procedures in a fashion that seems likely to engender controversy.

Our speakers will share their experience on the issues and advice that will help us better understand how IP affects the industry.

Program

7:30 am Light Breakfast and Networking
8:00 am Panel Discussion with:

        • Catherine Maresh, Senior Patent Counsel, Medtronics
        • Tod Stoltz, Manager Technology Business Development, UC Davis Health System, Office of Research, Technology and Industry Alliances
        • Roger Werne, Senior Advisor for Industrial Partnership, Lawrence Livermore National Laboratory
        • Moderated by: John E. Hamer, Entrepreneur-in-Residence, Burrill & Company

Bios

MODERATOR

John E. Hamer, Entrepreneur-in-Residence, Burrill & Company

John joined Burrill & Company in November 2003 as Entrepreneur-In-Residence. John helped to build Paradigm Genetics Inc. a publicly-traded biotechnology company in Research Triangle Park, North Carolina from its beginning in 1998 serving in various capacities as Director of Microbial Research, Vice President of Research, Chief Scientific Officer, Vice President for Business Development and Interim President and CEO. John received his Ph.D. in Microbiology from the University of California, Davis in 1987 and was a visiting scientist at Dupont’s Central Research and Development from 1987 to 1989. He served on the faculty of Purdue University where he held the positions of Assistant Professor (’89-’90), Associate Professor (’92-’98), Professor (’98-’00) and Adjunct Professor of Microbiology and Immunology at Indiana University/Purdue University Medical School. He currently holds an honorary position as Adjunct Professor of Biological Sciences. John has received numerous grants and awards of distinction throughout his career including a David and Lucille Packard Fellowship (1990-1995) and the National Science Foundation Presidential Faculty Fellowship (1993-1998). He has served on numerous scientific review and biotechnology advisory boards including those at the National Institutes of Health, the National Science Foundation, Purdue Alumni Science Advisory Board and North Carolina Genomic and Bioinformatics Consortium. Mr. Hamer serves on the Boards of Directors of AgraQuest (observer), Chlorogen, CropDesign (observer) and E-Markets. John recently co-founded and serves as CEO/President of Arete Therapeutics Inc., a cardiovascular drug development company.

SPEAKERS

Catherine Maresh, Senior Patent Counsel, Medtronics As Senior Patent Counsel of Medtronic Vascular, Inc.

Catherine handles patent and other intellectual property matters, including worldwide IP and litigation strategy. In addition to working with employees in the U.S., she works with the employees located at Medtronic’s Galway, Ireland facility. Medtronic’s Galway facility is one of two industrial partners in the Regenerative Medicine Institute (REMEDI) based at the National University of Ireland-Galway. REMEDI is a biomedical research centre focusing on gene therapy and stem cell research with the aim of regeneration and repair of tissues. Prior to joining Medtronic in 1999, Catherine practiced IP litigation and prosecution at the law firm of Haugen & Nikolai, P.A. for eight years in Minneapolis, Minnesota. Catherine is registered to practice in Minnesota, California, and before the U.S. Patent Office. Medtronic is the world leader in medical technology providing lifelong solutions for people with chronic disease. Medtronic’s vascular division focuses on treating coronary vascular, peripheral vascular, endovascular, and neurovascular disease. Medtronic Vascular offers a full complement of products for interventional procedures, including stents, drug-coated stents, stent grafts, balloon angioplasty catheters, guiding catheters, guidewires, and diagnostic catheters and accessories.

Tod Stoltz, Manager Technology Business Development, UC Davis Health System, Office of Research Technology and Industry Alliances

Roger Werne, Senior Advisor for Industrial Partnership, Lawrence Livermore National Laboratory.

Dr. Werne has broad experience in the commercialization of technology developed within the Lawrence Livermore National Laboratory. In the late eighties he started and led the LLNL Industrial Partnering program while he was Associate Director for Engineering. Engineering at LLNL was an organization of approximately 2,500 people that supported all Laboratory Programs including nuclear weapons, nonproliferation, advanced conventional defense, inertial confinement and magnetic fusion, energy research, and biotechnology. In 1995 he co-founded ITI Medical Technologies, a medical device start-up company focused on the field of Magnetic Resonance Image(MRI) guided surgery, a new minimally invasive surgical paradigm. In late 1999 he rejoined the Laboratory as Chief Engineer for the NAI/Homeland Security Directorate having the mission of countering the proliferation and use of weapons of mass destruction(WMD) against the United States.
Dr. Werne received his Ph.D. in Structures and Solid Mechanics from the University of California at Berkeley. Dr. Werne is also a pole vaulter in Masters Track & Field ranked in the top five in the U.S. in 2005 in his age group and a part time Assistant Track and Field Coach at a local high school.

 

Photo: Myleen Hollero

Top